Logo-bi
BioImpacts. 2022;12(2): 139-146. doi: 10.34172/bi.2021.23378
PMID: 35411293        PMCID: PMC8905590

Original Research

The active lung microbiota landscape of COVID-19 patients through the metatranscriptome data analysis

Yang Han 1,2 ORCID, Zhilong Jia 1,2 * ORCID, Jinlong Shi 1,2, Weidong Wang 1,2 * , Kunlun He 1,2 *

Cited by CrossRef: 18

1- Al‐Emran H, Rahman S, Hasan M, Ul Alam R, Islam O, Anwar A, Jahid M, Hossain A. Microbiome analysis revealing microbial interactions and secondary bacterial infections in COVID‐19 patients comorbidly affected by Type 2 diabetes. Journal of Medical Virology. 2023;95(1) [Crossref]
2- Taherkhani H, KavianFar A, Aminnezhad S, Lanjanian H, Ahmadi A, Azimzadeh S, Masoudi-Nejad A. Deciphering the impact of microbial interactions on COPD exacerbation: An in-depth analysis of the lung microbiome. Heliyon. 2024;10(4):e24775 [Crossref]
3- SeyedAlinaghi S, Afzalian A, Pashaei Z, Varshochi S, Karimi A, Mojdeganlou H, Mojdeganlou P, Razi A, Ghanadinezhad F, Shojaei A, Amiri A, Dashti M, Ghasemzadeh A, Dadras O, Mehraeen E, Afsahi A. Retracted: Gut microbiota and COVID‐19: A systematic review. Health Science Reports. 2023;6(2) [Crossref]
4- Bencze D, Fekete T, Pázmándi K. Correlation between Type I Interferon Associated Factors and COVID-19 Severity. IJMS. 2022;23(18):10968 [Crossref]
5- Pandey H, Lal D. Exploring Bacterial Diversity: How Far Have We Reached?. 2023;62(3-4):117 [Crossref]
6- Hou K, Wu Z, Chen X, Wang J, Zhang D, Xiao C, Zhu D, Koya J, Wei L, Li J, Chen Z. Microbiota in health and diseases. Sig Transduct Target Ther. 2022;7(1) [Crossref]
7- Neag M, Vulturar D, Gherman D, Burlacu C, Todea D, Buzoianu A. Gastrointestinal microbiota: A predictor of COVID-19 severity?. World J Gastroenterol. 2022;28(45):6328 [Crossref]
8- Mizutani T, Ishizaka A, Koga M, Tsutsumi T, Yotsuyanagi H. Role of Microbiota in Viral Infections and Pathological Progression. Viruses. 2022;14(5):950 [Crossref]
9- Yadav A, Pandey R. Viral infectious diseases severity: co-presence of transcriptionally active microbes (TAMs) can play an integral role for disease severity. Front Immunol. 2022;13 [Crossref]
10- Kamau E, Yang S. Metagenomic Sequencing of Positive Blood Culture Fluid for Accurate Bacterial and Fungal Species Identification: A Pilot Study. Microorganisms. 2023;11(5):1259 [Crossref]
11- Zsichla L, Müller V. Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. Viruses. 2023;15(1):175 [Crossref]
12- Roshni J, Sivakumar M, Bahammam F, Bhandi S, Patil S, Kamath M, Abusharha A, Ahmed S. New Ways to Protect the Host from SARS-CoV-2? Lung Microbiome Metabolites Inhibit STAT3 and Modulate the Immunological Network. OMICS: A Journal of Integrative Biology. 2023;27(5):237 [Crossref]
13- Marimón J, Sorarrain A, Ercibengoa M, Azcue N, Alonso M, Vidaur L. Lung microbiome on admission in critically ill patients with acute bacterial and viral pneumonia. Sci Rep. 2023;13(1) [Crossref]
14- Li W, Ma Z. The Upper Respiratory Tract Microbiome Network Impacted by SARS-CoV-2. Microb Ecol. 2023;86(2):1428 [Crossref]
15- Jochum M, Lee M, Curry K, Zaksas V, Vitalis E, Treangen T, Aagaard K, Ternus K. Analysis of bronchoalveolar lavage fluid metatranscriptomes among patients with COVID-19 disease. Sci Rep. 2022;12(1) [Crossref]
16- Wang S, Wu J, Ran D, Ou G, Chen Y, Xu H, Deng L, Chen X. Study of the Relationship between Mucosal Immunity and Commensal Microbiota: A Bibliometric Analysis. Nutrients. 2023;15(10):2398 [Crossref]
17- Alsayed A, Abed A, Khader H, Al-Shdifat L, Hasoun L, Al-Rshaidat M, Alkhatib M, Zihlif M. Molecular Accounting and Profiling of Human Respiratory Microbial Communities: Toward Precision Medicine by Targeting the Respiratory Microbiome for Disease Diagnosis and Treatment. IJMS. 2023;24(4):4086 [Crossref]
18- Gang J, Wang H, Xue X, Zhang S. Microbiota and COVID-19: Long-term and complex influencing factors. Front Microbiol. 2022;13 [Crossref]
19- Yasir M, Al-Sharif H, Al-Subhi T, Sindi A, Bokhary D, El-Daly M, Alosaimi B, Hamed M, Karim A, Hassan A, AlShawdari M, Alawi M, El-Kafrawy S, Azhar E. Analysis of the nasopharyngeal microbiome and respiratory pathogens in COVID-19 patients from Saudi Arabia. Journal of Infection and Public Health. 2023;16(5):680 [Crossref]
20- Valentino M, Esposito C, Colosimo S, Caprio A, Puzone S, Guarino S, Marzuillo P, Miraglia del Giudice E, Di Sessa A. Gut microbiota and COVID-19: An intriguing pediatric perspective. WJCC. 2022;10(23):8076 [Crossref]
21- Wu J, Liu W, Zhu L, Li N, Luo G, Gu M, Peng M, Zeng S, Wu S, Zhang S, Chen Q, Cai M, Cao W, Jiang Y, Luo C, Tian D, Shi M, Shu Y, Chang G, Luo H. Dysbiosis of oropharyngeal microbiome and antibiotic resistance in hospitalized COVID‐19 patients. Journal of Medical Virology. 2023;95(4) [Crossref]

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge